A bilateral aseptic pyogenic ventriculitis following a course of pembrolizumab, an anti-PD-1 immune checkpoint inhibitor treatment for metastatic small cell lung cancer - 02/06/22

Jean Terrier ^{a, b, c,} ⁎ , Alan Relecom ^d, Simon Borgeaud ^e, Claire Bridel ^e, Jörg Seebach ^f, Frédéric Assal ^e, Jean-Luc Reny ^{a, b}, Jacques Serratrice ^a

^a Division of General Internal Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland 

^b Geneva Platelet Group, Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland 

^c Clinical Pharmacology and Toxicology Division, Anesthesiology, Pharmacology, Intensive Care and Emergency Medicine Department, Geneva University Hospitals, 1205 Geneva, Switzerland 

^d Medical Oncology Division, Oncology Department, Geneva University Hospitals, 1205 Geneva, Switzerland 

^e Division of Clinical Neurosciences, Neurology Department, Geneva University Hospitals, 1205 Geneva, Switzerland 

^f Division of Immunology and Allergology, Geneva University Hospitals, 1205 Geneva, Switzerland 

^⁎Corresponding author. Division of General Internal Medicine University of Geneva Hospitals, 4, rue Gabrielle Perret-Gentil, 1205 Geneva, Switzerland.Division of General Internal Medicine University of Geneva Hospitals4, rue Gabrielle Perret-GentilGeneva1205Switzerland

Le texte complet de cet article est disponible en PDF.